pembrolizumab + cisplatin + etoposide + pegfilgrastim

This drug is a **combination therapy** used primarily in oncology and consists of four agents: pembrolizumab (a monoclonal antibody checkpoint inhibitor targeting the immune system), cisplatin (a platinum-based chemotherapeutic), etoposide (a topoisomerase II inhibitor), and pegfilgrastim (a pegylated granulocyte-colony stimulating factor to reduce neutropenia). **Pembrolizumab** works by inhibiting PD-1, thus enhancing T-cell antitumor activity. **Cisplatin** forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. **Etoposide** inhibits topoisomerase II function, causing DNA breakage and cell death. **Pegfilgrastim** stimulates neutrophil production to counteract chemotherapy-induced neutropenia. This combination has been researched, particularly for the *first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)* and potentially other malignancies where such regimens may be considered[1][3][5][7].

Other names

pembrolizumab + cisplatin + etoposide + pegfilgrastim